PharmaNetics losses increased a bit even as revenues also grew in the first quarter, the company said Wednesday.

Net loss was $2.5 million, or 25 cents a share, compared to $2.4 million a year ago.

Revenues increased to $1.2 million, up $300,000 from a year ago, as the company began selling its ENOX coagulation tests. The revenues were the same as reported in the fourth quarter.

PharmaNetics attributed part of the increased expenses to the launch of its ENOX sales force.